Table 3.
Number and percentage of CF patients heterozygous for the F508del and another mutation which showed an increase of serum total bilirubin and ALT after 1 year of ETI treatment in comparison with patients homozygous for the F508del mutation previously studied.
| Patients | n | Increased total bilirubin | Chi square | Increased ALT | Chi square | ||
|---|---|---|---|---|---|---|---|
| n | % | n | % | ||||
| All heterozygous for the F508del and another CFTR mutation | 105 | 82 | 78.1 | 0.008 | 66 | 62.9 | 0.003 |
| Heterozygous for the F508del and a class I–III CFTR mutation | 74 | 59 | 71.7 | 0.019 | 45 | 60.8 | 0.002 |
| Heterozygous for the F508del and a class IV–VI CFTR mutation | 22 | 16 | 72.7 | 0.009 | 16 | 72.7 | 0.239 |
| With liver steatosis | 34 | 27 | 79.4 | 0.035 | 19 | 55.9 | 0.002 |
| With no liver steatosis | 71 | 55 | 77.5 | 0.009 | 46 | 64.8 | 0.011 |
| F508del homozygous24 | 63 | 59 | 93.6 | – | 53 | 84.1 | – |